S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

ERBITUX Gets Approved in Japan for Colorectal Cancer (IMCL, BMY)

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

ImClone Systems Incorporated (NASDAQ: IMCL) has just announced that ERBITUX(R) has received marketing authorization in Japan for use in treating patients with advanced or metastatic colorectal cancer (mCRC).

This approval will allow the use of ERBITUX to treat Japanese patients with epidermal growth factor receptor (EGFR)-positive, curatively unresectable (inoperable), advanced or recurrent CRC, and it will allow the use of ERBITUX plus irinotecan in second and further lines of mCRC.

With this approval, ERBITUX is the first ever EGFR-targeted monoclonal antibody to be submitted for and receive marketing authorization in Japan.

Bristol-Myers Squibb (NYSE: BMY) has been Imclone’s commercialization partner.  We would also note that Merck KGAA (the German Merck, not U.S.) was also in the pact that was sent in for approval back in 2007.

Jon C. Ogg
July 16, 2008

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Douglas A. McIntyre |

Imclone’s ERBITUX Extends Life in Lung Cancer Patients (IMCL, BMY, DNA)

Shares of Imclone Systems Inc. (NASDAQ:IMCL) are screaming higher this morning on it meeting its primary endpoint of increasing survival…
The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J
247patrick |

The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J

Featured stocks include AbbVie and Johnson & Johnson.
The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca
247patrick |

The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca

Featured stocks include pharmaceutical giants Merck and Pfizer.
Positive Abivertinib Trial Results Push Sorrento Therapeutics (SRNE) 6.2% Higher
247patrick |

Positive Abivertinib Trial Results Push Sorrento Therapeutics (SRNE) 6.2% Higher

Biopharmaceutical outfit Sorrento Therapeutics rallied on Tuesday after the company released positive trial results from Abivertinib.
Douglas A. McIntyre |

Pre-Market Stock News (July 12, 2007)

(AA) Alcoa trading up 6% after Rio Tinto gave a higher rival bid over Alcoa’s buyout offer for Alcan.(AAON) AAON…
Merrill Lynch 4 Top Pharmaceutical Dividend Stocks To Own For 2016
Lee Jackson |

Merrill Lynch 4 Top Pharmaceutical Dividend Stocks To Own For 2016

Despite the howling from political candidates trying to make the top drug-makers their whipping boy in populist campaign efforts, the…
The Top Biopharma Events to Watch in 2020
Chris Lange |

The Top Biopharma Events to Watch in 2020

Here, 24/7 Wall St. presents a calendar of a few of the biggest clinical trial and FDA updates to watch…
Pharma Stock Roundup: J&J’s New ’23 View After Kenvue Separation, Regulatory Updates
247patrick |

Pharma Stock Roundup: J&J’s New ’23 View After Kenvue Separation, Regulatory Updates

Here is a recap of the week’s most important pharmaceutical stories.
Chris Lange |

5 Big FDA Decisions Expected in October

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of October and…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618